Cenix BioScience GmbH

DUBLIN, June 14, 2022 /PRNewswire/ -- The "Global Diagnostics Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering. The Global Diagnostics Partnering Terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 3,200 Diagnostics deals. The report provides a detailed understanding and analysis of how and why companies enter Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Diagnostics agreements announced in the life sciences since 2015. The report takes the reader through a comprehensive review Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Diagnostics partnering deals. The report presents financial deal term values for Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Diagnostics partnering field; both the leading deal values and most active Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 3,200 online deal records of actual Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. A comprehensive series of appendices is provided organized by Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostics partnering and dealmaking since 2015. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostics technologies and products. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering: Companion Diagnostics Imaging CT Endoscope Molecular and nuclear MRI Ultrasound X-ray PET SPECT Angiography Fluroscopy Mammography In vitro diagnostics Molecular diagnostics Prognostics Theranostics Key benefits Global Diagnostics Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits: In-depth understanding of Diagnostics deal trends since 2015 Access to headline, upfront, milestone and royalty data Detailed access to actual Diagnostics contracts entered into by leading biopharma companies Identify most active Diagnostics dealmakers since 2015 Insight into terms included in a Diagnostics partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies In Global Diagnostics Partnering Terms and Agreements 2015-2022, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Diagnostics dealmaking 2.1. Introduction 2.2. Diagnostics partnering over the years 2.3. Most active Diagnostics dealmakers 2.4. Diagnostics partnering by deal type 2.5. Diagnostics partnering by therapy area 2.6. Deal terms for Diagnostics partnering 2.6.1 Diagnostics partnering headline values 2.6.2 Diagnostics deal upfront payments 2.6.3 Diagnostics deal milestone payments 2.6.4 Diagnostics royalty rates Chapter 3 - Leading Diagnostics deals 3.1. Introduction 3.2. Top Diagnostics deals by value Chapter 4 - Most active Diagnostics dealmakers 4.1. Introduction 4.2. Most active Diagnostics dealmakers 4.3. Most active Diagnostics partnering company profiles Chapter 5 - Diagnostics contracts dealmaking directory 5.1. Introduction 5.2. Diagnostics contracts dealmaking directory Chapter 6 - Diagnostics dealmaking by technology type Appendices Appendix 1 - Diagnostics deals by company A-Z Appendix 2 - Diagnostics deals by stage of development Discovery Preclinical Phase I Phase II Phase III Regulatory Marketed Formulation Appendix 3 - Diagnostics deals by deal type Asset purchase Assignment Bigpharma outlicensing Co-development Collaborative R&D Co-market Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Litigation Manufacturing Marketing Material transfer Option Promotion Research Settlement Spin out Sub-license Supply Technology transfer Termination Warranty Appendix 4 - Diagnostics deals by therapy area Appendix 5 -Deal type definitions Appendix 6 - Further reading on dealmaking Companies Mentioned IBA IBM iCAD Icon IDS IDx Imbio Imec IMI IMRIS IPMD IQ-AI ITEL Item ITOCO Itus IXICO KEW Kore Lab21 LGC Image Analysis Great Basin Scientific Cosmo Bio Anpac Bio-Medical Science AmCad BioMed Canon BioMedical Cenix BioScience InGen BioSciences Array Biopharma Bliss Biopharmaceutical Agena Bioscience Crown Bioscience Akers Biosciences Akoya Biosciences Alume Biosciences Anixa Biosciences Arbor Biosciences For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets